Castle Biosciences lifted its full‑year 2026 revenue outlook to $365‑$375 million and posted an EPS of –$0.07, outpacing the –$0.41 consensus. The upgrade signals stronger test adoption and positions the company for positive adjusted EBITDA, a key profitability milestone for investors.

Key Highlights

  • Q2 2026 revenue climbed to $103.5 million from $86.2 million a year earlier.
  • Core test reports (DecisionDx‑Melanoma, TissueCypher) rose 32% versus Q2 2025.
  • Full‑year 2026 revenue guidance increased to $365‑$375 million, up from $345‑$355 million.
  • EPS of –$0.07 beat consensus estimate.

Castle Biosciences reported a strong second‑quarter performance, with revenue lifting to $103.5 million and core test volumes surging 32% year‑over‑year. The company responded by expanding its 2026 revenue forecast to a range of $365‑$375 million, an upgrade that narrows the gap to analysts’ expectations and underscores accelerating demand for its diagnostic panels. Investors note the move as a concrete indicator that the firm’s strategic focus on high‑value oncology and gastroenterology assays is delivering tangible commercial traction.

EPS Beats Consensus

CSTL reported EPS of –$0.07 for the quarter ended 2026‑06‑30, against a consensus estimate. The earnings beat came alongside a narrowed loss that included a non‑cash stock‑based compensation component, resulting in a net loss versus a net income in the comparable prior period. Adjusted EBITDA increased year‑over‑year, reflecting improved operating efficiency despite a dip in gross margin, while adjusted gross margin remained broadly stable.

By surpassing consensus EPS, the firm demonstrates resilience in a competitive diagnostic environment, setting the stage for profitability milestones later in the year.

Revenue and Test Volume Surge

Revenue for the quarter reached $103.5 million, a substantial increase from $86.2 million in the same quarter of 2025. The uplift was driven by a strong jump in core test reports: DecisionDx‑Melanoma deliveries increased, and TissueCypher Barrett’s Esophagus reports rose sharply. Although DecisionDx‑SCC and MyPath Melanoma volumes slipped modestly, the overall test mix bolstered top‑line growth.

Gross margin experienced a modest decline year‑over‑year, yet the company’s adjusted gross margin remained solid, suggesting pricing power and cost control are holding steady.

Market Reaction and Positioning

Following the guidance lift, Castle Biosciences’ shares moved higher, reflecting investor optimism about the updated outlook. Trading activity placed the stock within its recent price range, and market capitalization remained in the multi‑hundred‑million‑dollar tier. Short‑interest levels indicated limited pressure from bearish positions, and peer performance was largely unchanged, underscoring Castle’s relative strength amid a broadly neutral market environment.

Upcoming EBITDA Confirmation

Management signaled that adjusted EBITDA is expected to turn positive in the third quarter, fourth quarter, and for the full year, aligning with the revised revenue outlook. The forthcoming Q3 earnings release, slated for October 2026, will provide the first concrete confirmation of this profitability transition. Achievement of positive adjusted EBITDA will solidify the company’s financial footing and could catalyze further upside as the diagnostic portfolio expands.

Peers Moving on This News

  • AMN Healthcare Services Inc (AMN) little changed
  • Omada Health Inc (OMDA) little changed
  • OPKO Health Inc (OPK) down 0.4%

Analysis based on the Form 8-K filed 30 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.